BACKGROUND:Trivalent oral poliovirus vaccine (OPV) is known to interfere with monovalent rotavirus vaccine (RV1) immunogenicity. The interference caused by bivalent and monovalent OPV formulations, which will be increasingly used globally in coming years, has not been examined. We conducted a post hoc analysis to assess the effect of coadministration of different OPV formulations on RV1 immunogenicity. METHODS:Healthy infants in Matlab, Bangladesh, were randomized to receive 3 doses of monovalent OPV type 1 or bivalent OPV types 1 and 3 at either 6, 8, and 10 or 6, 10, and 14 weeks of age or trivalent OPV at 6, 10, and 14 weeks of age. All infants received 2 doses of RV1 at about 6 and 10 weeks of age. Concomitant administration was defined as RV1 and OPV given on the same day; staggered administration as RV1 and OPV given ≥1 day apart. Rotavirus seroconversion was defined as a 4-fold rise in immunoglobulin A titer from before the first RV1 dose to ≥3 weeks after the second RV1 dose. RESULTS: There were no significant differences in baseline RV1 immunogenicity among the 409 infants included in the final analysis. Infants who received RV1 and OPV concomitantly, regardless of OPV formulation, were less likely to seroconvert (47%; 95% confidence interval, 39%-54%) than those who received both vaccines staggered ≥1 day (63%; 57%-70%; P < .001). For staggered administration, we found no evidence that the interval between RV1 and OPV administration affected RV1 immunogenicity. CONCLUSIONS: Coadministration of monovalent, bivalent, or trivalent OPV seems to lower RV1 immunogenicity. CLINICAL TRIALS REGISTRATION: NCT01633216. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND: Trivalent oral poliovirus vaccine (OPV) is known to interfere with monovalent rotavirus vaccine (RV1) immunogenicity. The interference caused by bivalent and monovalent OPV formulations, which will be increasingly used globally in coming years, has not been examined. We conducted a post hoc analysis to assess the effect of coadministration of different OPV formulations on RV1 immunogenicity. METHODS: Healthy infants in Matlab, Bangladesh, were randomized to receive 3 doses of monovalent OPV type 1 or bivalent OPV types 1 and 3 at either 6, 8, and 10 or 6, 10, and 14 weeks of age or trivalent OPV at 6, 10, and 14 weeks of age. All infants received 2 doses of RV1 at about 6 and 10 weeks of age. Concomitant administration was defined as RV1 and OPV given on the same day; staggered administration as RV1 and OPV given ≥1 day apart. Rotavirus seroconversion was defined as a 4-fold rise in immunoglobulin A titer from before the first RV1 dose to ≥3 weeks after the second RV1 dose. RESULTS: There were no significant differences in baseline RV1 immunogenicity among the 409 infants included in the final analysis. Infants who received RV1 and OPV concomitantly, regardless of OPV formulation, were less likely to seroconvert (47%; 95% confidence interval, 39%-54%) than those who received both vaccines staggered ≥1 day (63%; 57%-70%; P < .001). For staggered administration, we found no evidence that the interval between RV1 and OPV administration affected RV1 immunogenicity. CONCLUSIONS: Coadministration of monovalent, bivalent, or trivalent OPV seems to lower RV1 immunogenicity. CLINICAL TRIALS REGISTRATION: NCT01633216. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: K Zaman; D A Sack; M Yunus; S E Arifeen; G Podder; T Azim; S Luby; R F Breiman; K Neuzil; S K Datta; A Delem; P V Suryakiran; H L Bock Journal: Vaccine Date: 2009-01-20 Impact factor: 3.641
Authors: Y A Maldonado; V Peña-Cruz; M de la Luz Sanchez; L Logan; S Blandón; M F Cantwell; S M Matsui; F Millan-Velasco; J L Valdespino; J Sepulveda Journal: J Infect Dis Date: 1997-03 Impact factor: 5.226
Authors: Manish Patel; Andi L Shane; Umesh D Parashar; Baoming Jiang; Jon R Gentsch; Roger I Glass Journal: J Infect Dis Date: 2009-11-01 Impact factor: 5.226
Authors: Penelope H Dennehy; Helen R Bertrand; Peter E Silas; Silvia Damaso; Leonard R Friedland; Remon Abu-Elyazeed Journal: Pediatrics Date: 2008-11 Impact factor: 7.124
Authors: Max Ciarlet; Ramei Sani-Grosso; Guojun Yuan; Guanghan F Liu; Penny M Heaton; Keith M Gottesdiener; José L Arredondo; Florian Schödel Journal: Pediatr Infect Dis J Date: 2008-10 Impact factor: 2.129
Authors: Joann F Gruber; Sylvia Becker-Dreps; Michael G Hudgens; M Alan Brookhart; James C Thomas; Michele Jonsson Funk Journal: Epidemiology Date: 2018-11 Impact factor: 4.822
Authors: Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes Journal: Nat Rev Dis Primers Date: 2017-11-09 Impact factor: 52.329
Authors: Minesh P Shah; Jacqueline E Tate; Jason M Mwenda; A Duncan Steele; Umesh D Parashar Journal: Expert Rev Vaccines Date: 2017-09-04 Impact factor: 5.217